RESUMEN
The accumulation of amyloid-beta (Aß) oligomers is recognized as a potential culprit in Alzheimer's disease (AD). Experimental studies show that melatonin, a hormone that mainly regulates circadian rhythm and sleep, can interact with Aß peptides and disrupt the formation of oligomers. However, how melatonin inhibits the oligomerization of soluble Aß is unclear. Here, by computational simulations, we investigate the effect of different levels of melatonin on the conformation of the Aß42 dimer. We find that the conformation of the Aß42 dimer is dependent on melatonin levels. When melatonin is absent, the dimer mainly forms a parallel ß-sheet in the CHC region. When one melatonin molecule is present, the overall conformation of the dimer does not change much, but the N-terminal of the dimer tends to adopt antiparallel ß-sheets. When two melatoinin molecules are present, the Aß42 dimer exhibits significant structural change, especially in its central region, resulting in a more compact conformation, and forms parallel ß-sheets in the C-terminal. This conformational difference induced by different levels of melatoinin can shed light on the protective role of melatonin.
Asunto(s)
Péptidos beta-Amiloides , Melatonina , Fragmentos de Péptidos , Humanos , Péptidos beta-Amiloides/química , Péptidos beta-Amiloides/metabolismo , Dimerización , Melatonina/química , Simulación de Dinámica Molecular , Fragmentos de Péptidos/química , Fragmentos de Péptidos/metabolismo , Conformación Proteica , Multimerización de Proteína/efectos de los fármacosRESUMEN
PURPOSE: Insomnia is a major health concern, and melatonin (MLT) is key for initiating sleep. Delivering MLT nasally can enhance brain bioavailability by targeting the olfactory region. This study aimed to fabricate MLT embedded microparticles for nasal delivery. METHODS: MLT-cyclodextrin (CD) derivatives complex microparticles (MCCMPs) were fabricated by spray drying and spray freeze drying MLT and CD derivative solutions. Phase solubility and 1H-1H ROSEY NMR analysis assessed MLT-CD assembly. The effects of formulation compositions and process parameters on microparticle structural attributes were investigated. The in vitro nasal release and deposition performances were evaluated by a modified paddle-over-disk apparatus and 3D-printed nasal cavity cast, respectively. RESULTS: Sodium sulphobutylether-ß-cyclodextrin (SBE-ß-CD) exhibited the best complexation ability with MLT, with the indole structure of MLT included in its cavity. Spray dried MCCMPs showed dense structure with high density, while the spray freeze dried counterpart showed the brittle and porous structure with low density. Despite the porous structure may promote the release rate of spray freeze dried samples, the high hydrophilicity of the CD derivative overshadows this advantage. Samples prepared by spray drying not only exhibited rapid release rates but also could deposit more effectively in the olfactory region, as they avoid breakage due to their higher mechanical strength. The optimal sample showed ~ 86.70% of the MLT released at 20 min and ~ 10.57% of the deposition fraction in the olfactory region. CONCLUSIONS: This work compares MCCMPs fabricated by spray drying and spray freeze drying, providing the optimal formulation and process combinations.
Asunto(s)
Administración Intranasal , Liofilización , Melatonina , Tamaño de la Partícula , Secado por Pulverización , beta-Ciclodextrinas , Melatonina/administración & dosificación , Melatonina/química , Melatonina/farmacocinética , Liofilización/métodos , beta-Ciclodextrinas/química , Solubilidad , Composición de Medicamentos/métodos , Microesferas , Liberación de Fármacos , Porosidad , Sistemas de Liberación de Medicamentos/métodosRESUMEN
Cartilage damage caused by injuries or degenerative diseases remains a major challenge in the field of regenerative medicine. In this study, we developed a composite hydrogel system for the delivery of melatonin and menstrual blood stem cells (MenSCs) to treat a rat model of cartilage defect. The composite delivery system was produced by incorporation of melatonin into the gelatin fibers and dispersing these fibers into calcium alginate hydrogels. Various characterization methods including cell viability assay, microstructure studies, degradation rate measurement, drug release, anti-inflammatory assay, and radical scavenging assay were used to characterize the hydrogel system. MenSCs were encapsulated within the nanocomposite hydrogel and implanted into a rat model of full-thickness cartilage defect. A 1.3 mm diameter drilled in the femoral trochlea and used for the in vivo study. Results showed that the healing potential of nanocomposite hydrogels containing melatonin and MenSCs was significantly higher than polymer-only hydrogels. Our study introduces a novel composite hydrogel system, combining melatonin and MenSCs, demonstrating enhanced cartilage repair efficacy, offering a promising avenue for regenerative medicine.
Asunto(s)
Gelatina , Hidrogeles , Melatonina , Nanocompuestos , Nanofibras , Melatonina/farmacología , Melatonina/química , Melatonina/administración & dosificación , Animales , Gelatina/química , Hidrogeles/química , Nanocompuestos/química , Ratas , Nanofibras/química , Femenino , Humanos , Cartílago/efectos de los fármacos , Ratas Sprague-Dawley , Menstruación/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Alginatos/química , Cicatrización de Heridas/efectos de los fármacos , Células Madre/citología , Células Madre/efectos de los fármacosRESUMEN
5-Methoxy-3-(5-methoxyindolin-2-yl)-1H-indole (3), whose structure was unambiguously elucidated by X-ray analysis, was identified as a multi-target compound with potential application in neurodegenerative diseases. It is a low nanomolar inhibitor of QR2 (IC50 = 7.7 nM), with greater potency than melatonin and comparable efficacy to the most potent QR2 inhibitors described to date. Molecular docking studies revealed the potential binding mode of 3 to QR2, which explains its superior potency compared to melatonin. Furthermore, compound 3 inhibits hMAO-A, hMAO-B and hLOX-5 in the low micromolar range and is an excellent ROS scavenger. In phenotypic assays, compound 3 showed neuroprotective activity in a cellular model of oxidative stress damage, it was non-toxic, and was able to activate neurogenesis from neural stem-cell niches of adult mice. These excellent biological properties, together with its both good in silico and in vitro drug-like profile, highlight compound 3 as a promising drug candidate for neurodegenerative diseases.
Asunto(s)
Melatonina , Simulación del Acoplamiento Molecular , Neurogénesis , Fármacos Neuroprotectores , Fármacos Neuroprotectores/farmacología , Fármacos Neuroprotectores/química , Fármacos Neuroprotectores/síntesis química , Melatonina/farmacología , Melatonina/química , Animales , Ratones , Humanos , Relación Estructura-Actividad , Neurogénesis/efectos de los fármacos , Estructura Molecular , Descubrimiento de Drogas , Quinona Reductasas/antagonistas & inhibidores , Quinona Reductasas/metabolismo , Inhibidores Enzimáticos/farmacología , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/síntesis química , Relación Dosis-Respuesta a DrogaRESUMEN
Aim: Cancer constitutes the second leading cause of death worldwide, with conventional therapies limited by significant side effects. Melatonin (MEL), a natural compound with antitumoral properties, suffers from instability and low solubility. To overcome these issues, MEL was encapsulated into nanostructured lipid carriers (MEL-NLC) containing rosehip oil to enhance stability and boost its antitumoral activity.Methods: MEL-NLC were optimized by a design of experiments approach and characterized for their physicochemical properties. Stability and biopharmaceutical behavior were assessed, along with interaction studies and in vitro antitumoral efficacy against various cancer cell lines.Results: Optimized MEL-NLC exhibited desirable physicochemical characteristics, including small particle size and sustained MEL release, along with long-term stability. In vitro studies demonstrated that MEL-NLC selectively induced cytotoxicity in several cancer cell lines while sparing healthy cells.Conclusion: MEL-NLC represent a promising alternative for cancer, combining enhanced stability and targeted antitumoral activity, potentially overcoming the limitations of conventional treatments.
Despite current advances, cancer is the second cause of death worldwide, but conventional therapies have side effects and limited efficacy. Natural therapies are emerging as suitable alternatives and, among them, Melatonin is a well-known compound with antitumoral properties. However, it is degraded by light, decreasing its therapeutical activity. In order to effectively deliver Melatonin into cancer cells, it has been encapsulated into biodegradable nanoparticles containing rosehip oil, which may boost the antitumoral properties. These nanoparticles have been optimized, showing a small size and a high Melatonin encapsulation, sustained drug release and good stability. Furthermore, in vitro studies demonstrated antitumoral activity against several cancer cell lines, also showing a high internalization inside them. Moreover, studies conducted using chicken embryonated eggs, showed that nanoparticles were non-toxic, thus confirming its promising therapeutical applications.
Asunto(s)
Antineoplásicos , Portadores de Fármacos , Lípidos , Melatonina , Nanoestructuras , Tamaño de la Partícula , Melatonina/farmacología , Melatonina/química , Melatonina/administración & dosificación , Humanos , Portadores de Fármacos/química , Lípidos/química , Nanoestructuras/química , Línea Celular Tumoral , Antineoplásicos/farmacología , Antineoplásicos/química , Antineoplásicos/administración & dosificación , Liberación de Fármacos , Supervivencia Celular/efectos de los fármacos , Neoplasias/tratamiento farmacológico , Estabilidad de MedicamentosRESUMEN
In this study, a formulation of NaGdF4:Tm/Er@NaGdF4 (core@shell) UCNPs loaded with melatonin drug was synthesized. The novel melatonin-loaded UCNPs were then encapsulated within NIR-responsive biopolymeric chitosan (CS) based polymersome and investigated against gastric cancer (HGC27 & AGS) cells. The photolysis of the ONB moiety and disruption of the disulfide linkage in the polymersome induced by NIR light facilitated by the NaGdF4:Tm/Er@NaGdF4 UCNPs and GSH results in an increased release of melatonin drug. The DLS and zeta potential measurements exhibit a reduced particle size (21.9 ± 3.56 nm) and a low zeta potential (17.91 mV). Furthermore, drug release profiles demonstrated superior melatonin drug release (79.78 %) at pH 5.0 for CS-polymersome-coated melatonin-UCNPs resembling the Hixson-Crowell model. Remarkably, CS-polymersome-coated melatonin-UCNPs exhibit excellent anti-proliferative properties for HGC27 (IC50 = 0.096 µM) and AGS (IC50 = 0.16 µM) cancer cells. The flow cytometry data demonstrate a significant elevation in ROS levels which promoted cell death in both HGC-27 and AGS cells. The observed cell mortality in HGC-27 and AGS cells is primarily caused by the destruction of the nucleus, mtDNA, rupture of disulfide (R-S-S-R) bonds, and nuclear DNA. Contrarily, L929 and HUVECs cells incubated with CS-polymersome coated melatonin-UCNPs (100 µg/mL) reveal a notable cell viability of 88.7 % and 93 % indicating superior biocompatibility. The western blotting analysis revealed the induction of autophagy by CS-polymersome-coated melatonin-UCNPs which subsequently led to apoptosis by regulating the ROS/PI3K/Akt/mTOR molecular signaling pathway.
Asunto(s)
Quitosano , Melatonina , Nanopartículas , Fosfatidilinositol 3-Quinasas , Proteínas Proto-Oncogénicas c-akt , Especies Reactivas de Oxígeno , Transducción de Señal , Neoplasias Gástricas , Serina-Treonina Quinasas TOR , Melatonina/farmacología , Melatonina/química , Quitosano/química , Quitosano/farmacología , Humanos , Serina-Treonina Quinasas TOR/metabolismo , Proteínas Proto-Oncogénicas c-akt/metabolismo , Neoplasias Gástricas/tratamiento farmacológico , Neoplasias Gástricas/metabolismo , Neoplasias Gástricas/patología , Especies Reactivas de Oxígeno/metabolismo , Transducción de Señal/efectos de los fármacos , Nanopartículas/química , Fosfatidilinositol 3-Quinasas/metabolismo , Línea Celular Tumoral , Rayos Infrarrojos , Apoptosis/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Liberación de Fármacos , Supervivencia Celular/efectos de los fármacosRESUMEN
Vesicants are chemical warfare agents (CWAs) capable of causing severe skin damage and systemic toxicity. Melatonin, known for its anti-inflammatory and antioxidant properties, can mitigate the effects of these agents. Self-nano-emulsifying drug delivery systems (SNEDDS) containing a high melatonin concentration (5 %, 50 mg/g) were optimized using a quality-by-design approach from biocompatible, non-irritant excipients with a particle size of about 100 nm. The melatonin-loaded SNEDDS showed a 43-fold greater permeability than a conventional melatonin cream. Chemical stability at ambient temperature (25 °C) was maintained for one year. The preparation of optimised melatonin-loaded SNEDDS using a simple mixing method was compared to microfluidic micromixers. Mixing was successfully achieved using a 3D-printed (fused deposition modeling or stereolithography) T-shaped toroidal microfluidic chip (with a channel geometry optimized by computational fluid dynamics), resulting in a scalable, continuous process for the first time with a substantial reduction in preparation time compared to other conventional mixing approaches. No statistically significant differences were observed in the key quality attributes, such as particle size and melatonin loading, between mixing method till kinetic equilibrium solubility is reached and mixing using the 3D-printed micromixers. This scalable, continuous, cost-effective approach improves the overall efficiency of SNEDDS production, reduces the cost of quality control for multiple batches, and demonstrates the potential of continuous microfluidic manufacture with readily customizable 3D-printed micromixers at points of care, such as military bases.
Asunto(s)
Antioxidantes , Sistemas de Liberación de Medicamentos , Emulsiones , Melatonina , Microfluídica , Tamaño de la Partícula , Permeabilidad , Impresión Tridimensional , Absorción Cutánea , Melatonina/química , Melatonina/administración & dosificación , Melatonina/farmacología , Antioxidantes/química , Antioxidantes/administración & dosificación , Antioxidantes/farmacología , Microfluídica/métodos , Absorción Cutánea/efectos de los fármacos , Excipientes/química , Estabilidad de Medicamentos , Solubilidad , Administración Cutánea , Piel/metabolismo , Piel/efectos de los fármacos , Composición de Medicamentos/métodos , Dispositivos Laboratorio en un ChipRESUMEN
The objective of the present study was to optimize the microwave-assisted synthesis of the acrylamide graft copolymer of Acacia nilotica gum (AM-co-ANG). Furthermore, graft copolymer was used for the formulation of a nanoparticulate system using a novel top to bottom solvent antisolvent technique for the delivery of melatonin. Grafting of ANG was optimized by using 32 factorial design, where concentrations of polymer and monomer (acrylamide) were used as independent variables and swelling index in acidic (0.1 N HCl) and basic (1 N NaOH) pH. Grafted polymers were further used to develop and optimize nanoparticulate system using concentration of the graft copolymer and concentration of drug as independent variables. The size of the nanoformulation and entrapment efficiency were selected as dependent variables. Difference in infrared spectrum and absorbance maxima in the ultraviolet region confirm that grafting has taken place. Porous structure and a higher contact angle confirmed hydrophobic nature of AM-co-ANG as compared with the native polymer. Acrylamide graft copolymers show more swelling in 1 N NaOH as compared with 0.1 N HCl. In vitro toxicity studies in hepatic (HepG2 cell line), brain (SHSY5Y cell line), and skin (HaCaT cell line) cells easily predict that synthesized polymer have no cytotoxicity. The entrapment efficiency ranged from 55.24 ± 1.35% to 73.21 ± 1.83%. A nonlinear correlation was observed between independent and dependent variables, as confirmed by multivariate analysis of variance, surface regression, and the correlation report. The prepared formulations were able to release drug up to 12 h. The regression coefficient easily predicted that most of the formulations followed Baker-Lonsdale drug release kinetics.
Asunto(s)
Acrilamida , Melatonina , Nanopartículas , Acrilamida/química , Nanopartículas/química , Humanos , Melatonina/farmacología , Melatonina/química , Células Hep G2 , Goma Arábiga/química , Acacia/química , Estabilidad de Medicamentos , Tamaño de la Partícula , Supervivencia Celular/efectos de los fármacosRESUMEN
Despite the fact that several rheumatoid arthritis treatments have been utilized, none of them achieved complete joint healing and has been accompanied by several side effects that compromise patient compliance. This study aims to provide an effective safe RA treatment with minimum side effects through the encapsulation of melatonin (MEL) in hyalurosomes and loading these hyalurosomes in collagen thermos-sensitive poloxamer 407 (PCO) hydrogels, followed by their intra-articular administration in AIA model rats. In vitro characterization of MEL-hyalurosomes and PCO hydrogel along with in vivo evaluation of the selected formulation were conducted. Particle size, PDI and EE % of the selected formulation were 71.5 nm, 0.09 and 90 %. TEM micrographs demonstrated that the particles had spherical shape with no aggregation signs. Loading PCO hydrogels with MEL-hyalurosomes did not cause significant changes in pH although it increased its viscosity and injection time. FTIR analysis showed that no interactions were noted among the delivery system components. In vivo results revealed the superior effect of MEL-hyalurosomes PCO hydrogel over MEL-PCO hydrogel and blank PCO hydrogels in improving joint healing, cartilage repair, pannus formation and cell infiltrations. Also, MEL-hyalurosomes PCO hydrogel group showed comparable levels of TNF-α, IL1, MDA, NRF2 and HO-1 with the negative control group. These findings highlight the MEL encapsulation role in augmenting its pharmacological effects along with the synergistic effect of hyaluronic acid in hyalurosomes and collagen in PCO hydrogel in promoting joint healing.
Asunto(s)
Artritis Reumatoide , Colágeno , Hidrogeles , Melatonina , Poloxámero , Animales , Melatonina/administración & dosificación , Melatonina/química , Melatonina/farmacología , Hidrogeles/química , Hidrogeles/administración & dosificación , Colágeno/química , Artritis Reumatoide/tratamiento farmacológico , Poloxámero/química , Masculino , Inyecciones Intraarticulares , Ratas , Artritis Experimental/tratamiento farmacológico , Ratas Wistar , Temperatura , Tamaño de la Partícula , Portadores de Fármacos/químicaRESUMEN
The combined chemotoxicity and radiotoxicity associated with uranium, utilized in nuclear industry and military applications, poses significant threats to human health. Among uranium pollutants, uranyl is particularly concerning due to its high absorptivity and potent nephrotoxicity in its + 6 valence state. Here, we have serendipitously found Na2SeO3 facilitates the conversion of U(VI) to U(IV) precipitates. A novel approach involving nano-chitosan loaded internally with melatonin and externally modified with selenite (NPs Cs-Se/MEL) was introduced. This modification not only enhances the conversion of U(VI) to U(IV) but also preserves the spherical nanostructure and specific surface area, leading to increased adsorption of U(VI) compared to unmodified samples. Selenite modification improves lysosomal delivery in HEK-293 T cells and kidney distribution of the nanoparticles. Furthermore, NPs Cs-Se/MEL demonstrated a heightened uranium concentration in urine and exhibited remarkable efficiency in uranium removal, resulting in a reduction of uranium deposition in serum, kidneys, and femurs by up to 52.02 %, 46.79 %, and 71.04 %, respectively. Importantly, NPs Cs-Se/MEL can be excreted directly from the kidneys into urine when carrying uranium. The results presented a novel mechanism for uranium adsorption, making selenium-containing nano-materials attractive for uranium sequestration and detoxification.
Asunto(s)
Quitosano , Melatonina , Nanopartículas , Ácido Selenioso , Uranio , Humanos , Uranio/química , Células HEK293 , Melatonina/administración & dosificación , Melatonina/química , Melatonina/farmacocinética , Quitosano/química , Nanopartículas/química , Ácido Selenioso/química , Animales , Riñón/metabolismo , Riñón/efectos de los fármacos , Adsorción , Masculino , Distribución TisularRESUMEN
Effective treatment of infected bone defects resulting from multi-drug resistant bacteria (MDR) has emerged as a significant clinical challenge, highlighting the pressing demand for potent antibacterial bone graft substitutes. Mesoporous nanoparticles have been introduced as a promising class of biomaterials offering significant properties for treating bone infections. Herein, we synthesize antibacterial mesoporous hydroxyapatite substituted with zinc and gallium (Zn-Ga:mHA) nanoparticles using a facile sol-gel method. The resulting mesoporous nanoparticles are applied for the controlled release of melatonin (Mel). Zn-Ga:mHA nanoparticles with an average particle size of 36 ± 3 nm and pore size of 10.6 ± 0.4 nm reveal a Mel loading efficiency of 58 ± 1%. Results show that 50% of Mel is released within 20 h and its long-term release is recorded up to 50 h. The Zn-Ga:mHA nanoparticles exhibit highly effective antibacterial performance as reflected by a 19 ± 1% and 8 ± 2% viability reduction in Escherichia coli and Staphylococcus bacteria, respectively. Noticeably, Mel-loaded Zn-Ga:mHA nanoparticles are also cytocompatible and stimulate in vitro osteogenic differentiation of human mesenchymal stem cells (hMSCs) without any osteoinductive factor. In vivo studies in a rabbit skull also show significant regeneration of bone during 14 days. In summary, Mel-loaded Zn-Ga:mHA nanoparticles provide great potential as an antibacterial and osteogenic component in bone substitutes like hydrogels, scaffolds, and coatings.
Asunto(s)
Antibacterianos , Regeneración Ósea , Durapatita , Galio , Melatonina , Células Madre Mesenquimatosas , Nanopartículas , Zinc , Galio/química , Galio/farmacología , Galio/administración & dosificación , Melatonina/farmacología , Melatonina/administración & dosificación , Melatonina/química , Durapatita/química , Durapatita/farmacología , Animales , Zinc/química , Zinc/farmacología , Zinc/administración & dosificación , Antibacterianos/farmacología , Antibacterianos/química , Antibacterianos/administración & dosificación , Conejos , Humanos , Nanopartículas/química , Nanopartículas/administración & dosificación , Células Madre Mesenquimatosas/efectos de los fármacos , Regeneración Ósea/efectos de los fármacos , Porosidad , Escherichia coli/efectos de los fármacos , Osteogénesis/efectos de los fármacos , Staphylococcus aureus/efectos de los fármacosRESUMEN
Melatonin acts as a potential regulator of cadmium (Cd) tolerance in rice. However, its practical value in rice production remains unclear. To validate the hypothesis that melatonin affects Cd accumulation and rice quality, a series of experiments were conducted. The results showed that exogenous melatonin application was associated with reduced Cd accumulation (23-43%) in brown rice. Fourier transform infrared spectroscopy (FTIR) analysis showed that exogenous melatonin affected the rice protein secondary structure and starch short-range structure. Metabolomics based on LC-MS/MS revealed that exogenous melatonin altered the brown rice metabolic profile, decreased fatty acid metabolite content, but increased amino acid metabolite, citric acid, melatonin biosynthetic metabolite, and plant hormone contents. These findings indicate that exogenous melatonin can effectively reduced Cd accumulation and improve rice quality through metabolic network regulation, serving as an effective treatment for rice cultivated in Cd-contaminated soil.
Asunto(s)
Cadmio , Melatonina , Oryza , Contaminantes del Suelo , Oryza/metabolismo , Oryza/química , Oryza/crecimiento & desarrollo , Cadmio/metabolismo , Cadmio/análisis , Cadmio/química , Melatonina/metabolismo , Melatonina/química , Melatonina/análisis , Contaminantes del Suelo/metabolismo , Contaminantes del Suelo/química , Proteínas de Plantas/metabolismo , Proteínas de Plantas/química , Espectrometría de Masas en TándemRESUMEN
The bone immune microenvironment can influence the occurrence and progression of bone defects. To date, research on promoting macrophage M2 polarization to improve bone injury repair has been insufficient. In this study, we designed an injectable poly(L-lactic acid) (PLLA) porous microsphere that forms calcium phosphate crystals on its surface by binding to melatonin, followed by bionanomimetic mineralization in vitro. The microsphere is injectable and degradable, and its release of melatonin (MT) and calcium phosphate (CaP) crystals promotes macrophage M2 polarization, reprogramming of macrophages, and enhanced osteogenesis. After LPS stimulation, the proportion of M2-polarized macrophages in the MS@CaP@MT group was 39.2 ± 2.7%, significantly higher than that in other groups (P < 0.05). Further, in the MS@CaP@MT group, rats exhibited bone mineral densities of 129.4 ± 12.8 mg cc-1 at 2 weeks and 171.6 ± 13.6 mg cc-1 at 4 weeks in the defect area, which were significantly higher than those in other groups (P < 0.05). Using an animal model of femoral condylar defects, we demonstrated that MT PLLA porous microspheres loaded with calcium phosphate crystals can improve the immune microenvironment and form a microsphere-centered osteogenesis model. This significantly accelerates bone defect repair and provides a potential strategy for bone defect treatment.
Asunto(s)
Fosfatos de Calcio , Macrófagos , Melatonina , Microesferas , Poliésteres , Fosfatos de Calcio/química , Animales , Melatonina/farmacología , Melatonina/química , Poliésteres/química , Porosidad , Ratas , Ratones , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Ratas Sprague-Dawley , Regeneración Ósea/efectos de los fármacos , Células RAW 264.7 , Masculino , Propiedades de Superficie , Tamaño de la Partícula , Osteogénesis/efectos de los fármacosRESUMEN
Melatonin receptors MT1 and MT2 are G protein-coupled receptors that mediate the effects of melatonin, a hormone involved in circadian rhythms and other physiological functions. Understanding the molecular interactions between these receptors and their ligands is crucial for developing novel therapeutic agents. In this study, we used molecular docking, molecular dynamics simulations, and quantum mechanics calculation to investigate the binding modes and affinities of three ligands: melatonin (MLT), ramelteon (RMT), and 2-phenylmelatonin (2-PMT) with both receptors. Based on the results, we identified key amino acids that contributed to the receptor-ligand interactions, such as Gln181/194, Phe179/192, and Asn162/175, which are conserved in both receptors. Additionally, we described new meaningful interactions with Gly108/Gly121, Val111/Val124, and Val191/Val204. Our results provide insights into receptor-ligand recognition's structural and energetic determinants and suggest potential strategies for designing more optimized molecules. This study enhances our understanding of receptor-ligand interactions and offers implications for future drug development.
Asunto(s)
Melatonina , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Unión Proteica , Receptor de Melatonina MT1 , Receptor de Melatonina MT2 , Melatonina/metabolismo , Melatonina/química , Receptor de Melatonina MT2/metabolismo , Receptor de Melatonina MT2/química , Receptor de Melatonina MT1/metabolismo , Receptor de Melatonina MT1/química , Humanos , Ligandos , Teoría Cuántica , Sitios de Unión , Indenos/química , Indenos/metabolismoRESUMEN
Natural products, known for their environmental safety, are regarded as a significant basis for the modification and advancement of fungicides. Melatonin, as a low-cost natural indole, exhibits diverse biological functions, including antifungal activity. However, its potential as an antifungal agent has not been fully explored. In this study, a series of melatonin derivatives targeting the mitogen-activated protein kinase (Mps1) protein of fungal pathogens were synthesized based on properties of melatonin, among which the trifluoromethyl-substituted derivative Mt-23 exhibited antifungal activity against seven plant pathogenic fungi, and effectively reduced the severity of crop diseases, including rice blast, Fusarium head blight of wheat and gray mold of tomato. In particular, its EC50 (5.4 µM) against the rice blast fungus Magnaporthe oryzae is only one-fourth that of isoprothiolane (22 µM), a commercial fungicide. Comparative analyzes revealed that Mt-23 simultaneously targets the conserved protein kinase Mps1 and lipid protein Cap20. Surface plasmon resonance assays showed that Mt-23 directly binds to Mps1 and Cap20. In this study, we provide a strategy for developing antifungal agents by modifying melatonin, and the resultant melatonin derivative Mt-23 is a commercially valuable, eco-friendly and broad-spectrum antifungal agent to combat crop disease.
Asunto(s)
Antifúngicos , Melatonina , Melatonina/farmacología , Melatonina/química , Melatonina/análogos & derivados , Antifúngicos/farmacología , Antifúngicos/química , Enfermedades de las Plantas/microbiología , Proteínas Fúngicas/metabolismo , Fungicidas Industriales/farmacología , Fungicidas Industriales/química , Fungicidas Industriales/síntesis químicaRESUMEN
Melatonin (MT) is a vital hormone controlling biorhythms, and optimizing its release in the human body is crucial. To address MT's unfavorable pharmacokinetics, we explored the inclusion complexes of MT with ß-cyclodextrin (ß-CD). Nano spray drying was applied to efficiently synthesize these complexes in three molar ratios (MT : ß-CD = 1 : 1, 2 : 1, and 1 : 2), reducing reagent use and expediting inclusion. The complex powders were characterized through thermal analyses (TGA and DSC), Fourier transform infrared spectroscopy (FTIR), and in vitro MT release measurements via high-performance liquid chromatography (HPLC). In parallel, computational studies were conducted, examining the stability of MT : ß-CD complexes by means of unbiased semi-empirical conformational searches refined by DFT, which produced a distribution of MT : ß-CD binding enthalpies. Computational findings highlighted that these complexes are stabilized by specific hydrogen bonds and non-specific dispersive forces, with stronger binding in the 1 : 1 complex, which was corroborated by in vitro release data. Furthermore, the alignment between simulated and experimental FTIR spectra demonstrated the quality of both the structural model and computational methodology, which was crucial to enhance our comprehension of optimizing MT's release for therapeutic applications.
Asunto(s)
Melatonina , beta-Ciclodextrinas , beta-Ciclodextrinas/química , Melatonina/química , Teoría Funcional de la Densidad , Liberación de Fármacos , Espectroscopía Infrarroja por Transformada de FourierRESUMEN
TPGS (D-α-tocopheryl polyethylene glycol 1000 succinate) polymeric micelles show interesting properties for ocular administration thanks to their solubilization capability, nanometric size and tissue penetration ability. However, micelles formulations are generally characterized by low viscosity, poor adhesion and very short retention time at the administration site. Therefore, the idea behind this work is the preparation and characterization of a crosslinked film based on xanthan gum that contains TPGS micelles and is capable of controlling their release. The system was loaded with melatonin and cyclosporin A, neuroprotective compounds to be delivered to the posterior eye segment. Citric acid and heating at different times and temperatures were exploited as crosslinking approach, giving the possibility to tune swelling, micelles release and drug release. The biocompatibility of the platform was confirmed by HET-CAM assay. Ex vivo studies on isolated porcine ocular tissues, conducted using Franz cells and two-photon microscopy, demonstrated the potential of the xanthan gum-based platform and enlightened micelles penetration mechanism. Finally, the sterilization step was approached, and a process to simultaneously crosslink and sterilize the platform was developed.
Asunto(s)
Administración Oftálmica , Preparaciones de Acción Retardada , Liberación de Fármacos , Micelas , Fármacos Neuroprotectores , Polisacáridos Bacterianos , Vitamina E , Polisacáridos Bacterianos/química , Animales , Porcinos , Fármacos Neuroprotectores/administración & dosificación , Fármacos Neuroprotectores/química , Fármacos Neuroprotectores/farmacocinética , Vitamina E/química , Vitamina E/administración & dosificación , Preparaciones de Acción Retardada/química , Ciclosporina/administración & dosificación , Ciclosporina/química , Melatonina/administración & dosificación , Melatonina/química , Melatonina/farmacología , Melatonina/farmacocinética , Esterilización , Reactivos de Enlaces Cruzados/química , Portadores de Fármacos/química , Ojo/efectos de los fármacos , Ojo/metabolismo , Sistemas de Liberación de Medicamentos/métodosRESUMEN
INTRODUCTION: In an attempt to circumvent the lipophilicity burden for the oral administration of new potent synthetic melatoninergic fluorine-substituted methoxyphenylalkyl amides, we conducted in vitro modified release studies using carefully selected matrix tablets' biopolymeric materials in different ratios. METHODS: In particular, we sought to attain release profiles of these analogues similar to that of the parent compound, the chronobiotic hormone Melatonin (MLT), and also of the commercially available drug, Circadin®. RESULTS: It was found that some of these systems, albeit being more lipophilic than MLT, mimic the in vitro release patterns of melatonin and Circadin®. CONCLUSION: Moreover, a number of these derivatives were proven suitable for dealing with sleep onset problems, whilst others for dealing with combined sleep onset/sleep maintenance dysfunctions.
Asunto(s)
Melatonina , Melatonina/química , Melatonina/administración & dosificación , Melatonina/farmacología , Administración Oral , Humanos , Amidas/química , Amidas/administración & dosificación , Amidas/síntesis química , Comprimidos , HalogenaciónRESUMEN
Skin is the largest organ of the human body functioning as a great primitive defensive barrier against different harmful environmental factors. However, it is damaged through varying injuries such as different wounds, burns, and skin cancers that cause disruption in internal organs and essential mechanisms of the body through inflammation, oxidation, coagulation problems, infection, etc. Melatonin is the major hormone of the pineal gland that is also effective in skin disorders due to strong antioxidant and anti-inflammatory features with additional desirable antiapoptotic, anti-cancer, and antibiotic properties. However, melatonin characteristics require improvements due to its limited water solubility, halflife and stability. The application of nanocarrier systems can improve its solubility, permeability, and efficiency, as well as inhibit its degradation and promote photostability. Our main purpose in the current review is to explore the possible role of melatonin and melatonin-containing nanocarriers in skin disorders focused on wounds. Additionally, melatonin's effect in regenerative medicine and its structures as a wound dressing in skin damage has been considered.
Asunto(s)
Melatonina , Nanoestructuras , Enfermedades de la Piel , Cicatrización de Heridas , Melatonina/farmacología , Melatonina/química , Humanos , Cicatrización de Heridas/efectos de los fármacos , Nanoestructuras/química , Enfermedades de la Piel/tratamiento farmacológico , Enfermedades de la Piel/patología , Animales , Antioxidantes/química , Antioxidantes/farmacología , Piel/efectos de los fármacos , Piel/patología , Piel/metabolismoRESUMEN
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid plaques in the brain. The toxicity of amyloid to neuronal cell surfaces arises from interactions between small intermediate aggregates, namely amyloid oligomers, and the cell membrane. The nature of these interactions changes with age and disease progression. In our previous work, we demonstrated that both membrane composition and nanoscale structure play crucial roles in amyloid toxicity, and that membrane models mimicking healthy neuron were less affected by amyloid than model membranes mimicking AD neuronal membranes. This understanding introduces the possibility of modifying membrane properties with membrane-active molecules, such as melatonin, to protect them from amyloid-induced damage. In this study, we employed atomic force microscopy and localized surface plasmon resonance to investigate the protective effects of melatonin. We utilized synthetic lipid membranes that mimic the neuronal cellular membrane at various stages of AD and explored their interactions with amyloid-ß(1-42) in the presence of melatonin. Our findings reveal that the early diseased membrane model is particularly vulnerable to amyloid binding and subsequent damage. However, melatonin exerts its most potent protective effect on this early-stage membrane. These results suggest that melatonin could act at the membrane level to alleviate amyloid toxicity, offering the most protection during the initial stages of AD.